Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Vinpocetine Chemo-induced Peripheral Neuropathy
Vinpocetine Chemo-induced Peripheral Neuropathy
According to research posted below, vinpocetine alleviates chemo-induced peripheral neuropathy. Again, according to research, some studies report that up to 75% of myeloma patients develop CIPN due to treatment-related nerve damage.
I linked this video because it explains nerve damage well.
How Peripheral Neuropathy Affects the Body
While there are few conventional therapies shown to treat CIPN, there are many non-conventional therapies such as vinpocetine that have been shown to alleviate CIPN.
- Myeloma-Chemotherapy-Induced Peripheral Neuropathy (CIPN) Therapy
- Chemotherapy-Induced Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Supplementation Mitigates Peripheral Neuropathy
Once again, there is a divide between what the FDA approves for the treatment of a side effect of MM treatment- CIPN in this case, and evidence-based but non-conventional therapies to treat CIPN.
I am a long-term MM survivor. Please email me at David.PeopleBeatingCancer@gmail.com to learn more about both conventional and non-conventional MM therapies.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Vinpocetine alleviates chemotherapy-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial biogenesis in mice
Highlights
- Repeated vinpocetine treatment attenuates mechanical, thermal, and cold hypersensitivities
- Vinpocetine downregulates AMPA and NR2B receptor expressions and suppresses PKC-α signaling in the spinal cord.
- Voltage-sensitive dye imaging reveals that vinpocetine reduces neuronal hyperexcitability in the spinal cord.
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of cancer treatment and is primarily driven by oxidative stress and mitochondrial dysfunction. Despite its clinical relevance, effective mechanism-based therapies remain limited.
Vinpocetine, a neuroprotective compound, has shown antioxidant, anti-inflammatory, and mitochondrial function-preserving effects; however, its efficacy in CIPN remains unknown.
This study aimed to evaluate the efficacy and underlying mechanisms of vinpocetine in a paclitaxel-induced CIPN mouse model.
In behavioral tests, acute administration of vinpocetine alleviated mechanical hypersensitivity, whereas repeated treatment provided sustained relief from:
- mechanical,
- thermal, and
- cold hypersensitivity.
Mechanistically, vinpocetine reduced mitochondrial reactive oxygen species (ROS), restored SOD2 levels, and activated mitochondrial biogenesis via the PGC-1α-NRF1-TFAM pathway, as shown by Western blot analysis.
In oxidative stress-induced pain models, vinpocetine also attenuated mechanical hypersensitivity, reinforcing its antioxidant properties. Voltage-sensitive dye imaging revealed reduced spinal neuronal hyperexcitability…
This preclinical study is the first to demonstrate that vinpocetine alleviates CIPN by enhancing mitochondrial biogenesis, reducing oxidative stress, and suppressing neuronal excitability in the spinal cord.
These results provide mechanistic insights into its effects on CIPN and support further translational research in this indication…
Medical uses
Vinpocetine has been used in many Asian and European countries for treatment of cerebrovascular disorders such as stroke and dementia for over three decades.[4]…
Side effects
Use during pregnancy may harm the baby or result in miscarriage.[2]
Adverse effects of vinpocetine include flushing, nausea, dizziness, dry mouth, transient hypo- and hyper-tension, headaches, heartburn, and decreased blood pressure.[9][17] FDA issued a statement in 2019 warning that “vinpocetine may cause a miscarriage or harm fetal development”.[18]
vinpocetine chemo-induced peripheral neuropathy
vinpocetine chemo-induced peripheral neuropathy
vinpocetine chemo-induced peripheral neuropathy